{"id":26477,"date":"2022-08-24T18:19:00","date_gmt":"2022-08-24T10:19:00","guid":{"rendered":"https:\/\/flcube.com\/?p=26477"},"modified":"2025-02-12T18:22:44","modified_gmt":"2025-02-12T10:22:44","slug":"lees-pharma-expands-global-rights-to-windtrees-kl4-surfactant-products","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=26477","title":{"rendered":"Lee&#8217;s Pharma Expands Global Rights to Windtree&#8217;s KL4 Surfactant Products"},"content":{"rendered":"\n<p>China-based Lee&#8217;s Pharmaceutical Holdings Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/0950:HKG\">HKG: 0950<\/a>) has expanded its licensing agreement with US-based Windtree Therapeutics, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/WINT:NASDAQ\">NASDAQ: WINT<\/a>), securing global exclusive rights to develop, manufacture, and commercialize KL4 surfactant products, including Surfaxin, Surfaxin LS, and Aerosurf. The revised deal, effective August 9, 2022, builds on the initial agreement signed in June 2017, which granted Lee&#8217;s Pharma exclusive rights in Asia.<\/p>\n\n\n\n<p><strong>Product Details<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Surfaxin and Surfaxin LS:<\/strong> Investigational synthetic peptides designed to treat respiratory distress syndrome (RDS) in premature infants by supplementing insufficient natural surfactants.<\/li>\n\n\n\n<li><strong>Aerosurf:<\/strong> A drug\/device combination that delivers aerosolized KL4 surfactant non-invasively, reducing the need for endotracheal intubation and mechanical ventilation. The product has fast-track status in the US and previously received orphan drug designation for RDS.<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Outlook<\/strong><br>The expanded agreement positions Lee&#8217;s Pharma to commercialize these products globally, leveraging Windtree&#8217;s innovative KL4 surfactant technology. The collaboration aims to address unmet needs in neonatal respiratory care, with potential to transform clinical outcomes and reduce healthcare costs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Lee&#8217;s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[941,165,1631,68,24,1632],"class_list":["post-26477","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-0950","tag-lees-pharmaceutical","tag-nasdaq-wint","tag-pediatric-drugs","tag-rare-orphan-disease-drugs","tag-windtree-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lee&#039;s Pharma Expands Global Rights to Windtree&#039;s KL4 Surfactant Products - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Lee&#039;s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree Therapeutics, Inc. (NASDAQ: WINT), securing global exclusive rights to develop, manufacture, and commercialize KL4 surfactant products, including Surfaxin, Surfaxin LS, and Aerosurf. The revised deal, effective August 9, 2022, builds on the initial agreement signed in June 2017, which granted Lee&#039;s Pharma exclusive rights in Asia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=26477\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee&#039;s Pharma Expands Global Rights to Windtree&#039;s KL4 Surfactant Products\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=26477\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-24T10:19:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T10:22:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26477#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26477\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee&#8217;s Pharma Expands Global Rights to Windtree&#8217;s KL4 Surfactant Products\",\"datePublished\":\"2022-08-24T10:19:00+00:00\",\"dateModified\":\"2025-02-12T10:22:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26477\"},\"wordCount\":177,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 0950\",\"Lee's Pharmaceutical\",\"NASDAQ: WINT\",\"Pediatric drugs\",\"Rare \\\/ orphan disease drugs\",\"Windtree Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26477#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26477\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=26477\",\"name\":\"Lee's Pharma Expands Global Rights to Windtree's KL4 Surfactant Products - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-08-24T10:19:00+00:00\",\"dateModified\":\"2025-02-12T10:22:44+00:00\",\"description\":\"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree Therapeutics, Inc. (NASDAQ: WINT), securing global exclusive rights to develop, manufacture, and commercialize KL4 surfactant products, including Surfaxin, Surfaxin LS, and Aerosurf. The revised deal, effective August 9, 2022, builds on the initial agreement signed in June 2017, which granted Lee's Pharma exclusive rights in Asia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26477#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26477\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26477#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee&#8217;s Pharma Expands Global Rights to Windtree&#8217;s KL4 Surfactant Products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee's Pharma Expands Global Rights to Windtree's KL4 Surfactant Products - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree Therapeutics, Inc. (NASDAQ: WINT), securing global exclusive rights to develop, manufacture, and commercialize KL4 surfactant products, including Surfaxin, Surfaxin LS, and Aerosurf. The revised deal, effective August 9, 2022, builds on the initial agreement signed in June 2017, which granted Lee's Pharma exclusive rights in Asia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=26477","og_locale":"en_US","og_type":"article","og_title":"Lee's Pharma Expands Global Rights to Windtree's KL4 Surfactant Products","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=26477","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-08-24T10:19:00+00:00","article_modified_time":"2025-02-12T10:22:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=26477#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=26477"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee&#8217;s Pharma Expands Global Rights to Windtree&#8217;s KL4 Surfactant Products","datePublished":"2022-08-24T10:19:00+00:00","dateModified":"2025-02-12T10:22:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=26477"},"wordCount":177,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 0950","Lee's Pharmaceutical","NASDAQ: WINT","Pediatric drugs","Rare \/ orphan disease drugs","Windtree Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=26477#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=26477","url":"https:\/\/flcube.com\/?p=26477","name":"Lee's Pharma Expands Global Rights to Windtree's KL4 Surfactant Products - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-08-24T10:19:00+00:00","dateModified":"2025-02-12T10:22:44+00:00","description":"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree Therapeutics, Inc. (NASDAQ: WINT), securing global exclusive rights to develop, manufacture, and commercialize KL4 surfactant products, including Surfaxin, Surfaxin LS, and Aerosurf. The revised deal, effective August 9, 2022, builds on the initial agreement signed in June 2017, which granted Lee's Pharma exclusive rights in Asia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=26477#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=26477"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=26477#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee&#8217;s Pharma Expands Global Rights to Windtree&#8217;s KL4 Surfactant Products"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26477"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26477\/revisions"}],"predecessor-version":[{"id":26478,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26477\/revisions\/26478"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}